{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-kidney-disease/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"85bf4dec-7d92-5c07-9468-68fd460fa54c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 57f984b7-e8be-48ab-883f-49747afc4fba --><h2>Changes</h2><!-- end field 57f984b7-e8be-48ab-883f-49747afc4fba -->","summary":null,"htmlStringContent":"<!-- begin item d0ae1401-018f-4c23-92e2-e8b779df8111 --><!-- begin field fdebacce-29e5-49f1-b805-0a6ccd2f6b35 --><p><strong>May 2020</strong> – minor update. Prescribing information has been added in response to the National Institute for Health and Care Excellence (NICE)<em> COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19</em> to reflect the advice during the COVID-19 pandemic.</p><p><strong>May 2020</strong> – minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>December 2019</strong> — minor update. Typo corrected.</p><p><strong>February to March 2019 </strong>— reviewed. A literature search was conducted in February 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has been updated in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care</em> (2015). The topic has undergone minor restructuring to improve navigation and clarity. The topic has been renamed 'Chronic kidney disease' and information on the management of people with diabetes mellitus and chronic kidney disease has been added to the section on <em>Management in primary care</em>. An <em>Assessment</em> node has been added to the section on <em>Diagnosis</em>. The prescribing information section has been updated.</p><!-- end field fdebacce-29e5-49f1-b805-0a6ccd2f6b35 --><!-- end item d0ae1401-018f-4c23-92e2-e8b779df8111 -->","topic":{"id":"cf2598e6-fd50-5f3b-8ae0-aad8ebd19ed8","topicId":"ae266062-cc1b-44e2-8118-44e1890750e3","topicName":"Chronic kidney disease","slug":"chronic-kidney-disease","lastRevised":"Last revised in May 2020","chapters":[{"id":"5036566c-74da-5f5a-8ad0-52200f66bacc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b4e7fb9-e75e-5183-b93f-5121d902b8aa","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75479619-9bb3-51b1-8d45-322a0183327c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"85bf4dec-7d92-5c07-9468-68fd460fa54c","slug":"changes","fullItemName":"Changes"},{"id":"e9caee39-e4d7-55ea-bba5-d1bfb037fab3","slug":"update","fullItemName":"Update"}]},{"id":"94be5ea4-6a52-53bd-9cff-cbc58599fb38","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"af9d912d-8cc7-598f-90cf-201a0152486f","slug":"goals","fullItemName":"Goals"},{"id":"e04a2acd-d3aa-5b29-afe8-4ff8a5cf2527","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c36c8ae1-59b3-5370-8b7b-c879c1c25d17","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb64e97-bb95-5733-ba72-d5da80477d5b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0cefa383-4a3f-5e37-8c1d-0cc7b2ba971c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c308ef71-7be3-579d-9b92-dd1e9164c74d","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"34f1f543-1b43-52aa-91e6-43d392ace4b2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"420f2db7-0bb3-5f08-a35d-671ffd9e83db","slug":"definition","fullItemName":"Definition"},{"id":"f36e5c98-76d5-563f-b7e3-a8e580d8edda","slug":"causes","fullItemName":"Causes"},{"id":"16745b88-79f5-5576-a0a4-704c8cb342e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82584375-f9fb-5690-9fe3-f2fb2586f2de","slug":"complications","fullItemName":"Complications"},{"id":"6ddacff5-19b6-5342-b340-25aecbf26dbd","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00dbd4ad-decc-5bde-b4a3-2599d730c702","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"cdd9f22d-7a2f-5fd6-a9e1-199b0c3ffdfa","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c6b6c8c3-633d-5062-9804-7b6711e7ddcd","slug":"assessment","fullItemName":"Assessment"},{"id":"3878fa85-9973-5158-8407-20d64dbf148d","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"579baee5-96e6-5639-a5ee-7dc30540dc8f","fullItemName":"Management","slug":"management","subChapters":[{"id":"07ec0bcd-8fb7-5ae7-87fd-2ff471574c5c","slug":"management-of-chronic-kidney-disease","fullItemName":"Scenario: Management of chronic kidney disease"},{"id":"44ceaa7d-a91b-5472-a7ab-e4bc448067ad","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"b0158ce5-7a78-50df-8843-ded7d59d08e3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a270530d-7db1-5b03-a1d8-8ff38e242ab9","slug":"ace-inhibitors-aiiras","fullItemName":"ACE-inhibitors and AIIRAs"}]},{"id":"50985320-3b22-5997-85d2-680285318de6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"168ee77d-eb0d-52d8-a32b-4bda877d21f0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c8ca80a7-ccf2-5a42-9b8e-72783e1f2131","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fe26a3ba-fa1b-5c97-8a08-e1f7d193447a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"854a26b2-4877-59ae-863e-99abcbcad667","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0af4d212-648e-5a4d-ad67-b1874a49688e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f180e32d-a855-558d-b666-d4c6804afe04","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ba009e6c-4065-55da-b6c5-bd179af81374","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"75479619-9bb3-51b1-8d45-322a0183327c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"0558846b-b7ca-5d25-951d-a81bfbf2a0af","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 1f08bfe8-5331-4a7d-89ea-fc4d072521bd --><h3>Previous changes</h3><!-- end field 1f08bfe8-5331-4a7d-89ea-fc4d072521bd -->","summary":null,"htmlStringContent":"<!-- begin item abaa8822-10e1-4785-8f74-e6702d7ff6c9 --><!-- begin field 82d0e26c-01a8-45a9-82e4-a3f0df310226 --><p><strong>May 2016 </strong>— minor update. Information on when to suspect a urological cancer has been deleted and a link provided to the CKS topic on Urological cancers and referral.</p><p><strong>October 2015 </strong>— minor update. The Prescribing information section has been updated to include advice from the Medicines and Healthcare products Regulatory Agency (MHRA) and the drug manufacturers that combination use of drugs from two classes of the renin-angiotensin system (RAS) blocking agents (for example an angiotensin-converting enzyme [ACE] inhibitor <em>plus </em>an angiotensin-II receptor antagonist or aliskiren) is not recommended (MHRA 2014). Common adverse effects of ACE-inhibitors have also been added, based on the manufacturer's 2015 Summary of Product Characteristics (SPC) for Tritace<sup>® </sup>(ramipril).</p><p><strong>December 2014 </strong>— minor update. Cilazapril preparations have been discontinued and removed from this topic in line with the British National Formulary (BNF) 2014.</p><p><strong>May 2014 to October 2014 </strong>— reviewed. A literature search was conducted in May 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. A number of significant changes have been made in line with the NICE guideline <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care </em>(2014) including:</p><ul><li>A new section on how to diagnose chronic kidney disease has been added.</li><li>A recommendation for laboratories to report estimated glomerular filtration rate (eGFR) by using the CKD-EPI equation.</li><li>A recommendation that eGFR cystatin C may be considered to confirm the presence of CKD for people with an eGFR between 45 to 59 mL/min/1.73 m<sup>2 </sup>with no proteinuria (ACR is less than 3mg/mmol) or other marker of kidney disease.</li><li>The classification of CKD has been updated.</li><li>The frequency of monitoring people with CKD has been updated.</li><li>The management sections have been updated.</li><li>A new recommendations on when to start a statin. These are now in line with the NICE guidance <em>Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em> (2014).</li></ul><p><strong>December 2013 </strong>— minor update. Prescribing information has been updated in line with the Summary of Product Characteristics (SPC) for perindopril.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>January to July 2009 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 82d0e26c-01a8-45a9-82e4-a3f0df310226 --><!-- end item abaa8822-10e1-4785-8f74-e6702d7ff6c9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}